These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36927246)

  • 1. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study.
    Caldarola G; Chiricozzi A; Megna M; Dapavo P; Giunta A; Burlando M; Malagoli P; Dini V; Mariani M; Fabbrocini G; Quaglino P; Bianchi L; Parodi A; Peris K; De Simone C
    Expert Opin Biol Ther; 2023 Apr; 23(4):365-370. PubMed ID: 36927246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
    Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
    Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
    Egeberg A; Bryld LE; Skov L
    J Am Acad Dermatol; 2019 Jul; 81(1):173-178. PubMed ID: 30914343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.
    Megna M; Potestio L; Camela E; Fabbrocini G; Ruggiero A
    Dermatol Ther; 2022 Sep; 35(9):e15667. PubMed ID: 35762107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience.
    Gönülal M; Altunay İK; Doğan S; Türkmen M; Balcı DD; Öztürkcan S
    Dermatol Ther; 2022 Dec; 35(12):e15955. PubMed ID: 36271759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García EA; Herrera-Ceballos E
    Dermatol Ther; 2020 May; 33(3):e13313. PubMed ID: 32181962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice.
    Caldarola G; Mariani M; Pirro F; Nicolotti N; Burlando M; Calabrese L; Parodi A; Peris K; De Simone C
    Expert Opin Biol Ther; 2021 Feb; 21(2):279-286. PubMed ID: 33170052
    [No Abstract]   [Full Text] [Related]  

  • 10. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
    Malagoli P; Dapavo P; Pavia G; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dini V; Girolomoni G; Guarneri C; Loconsole F; Narcisi A; Sampogna F; Travaglini M; Costanzo A
    Dermatol Ther; 2022 Aug; 35(8):e15608. PubMed ID: 35638250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study.
    Sherman S; Zloczower O; Noyman Y; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2020 Dec; 100(19):adv00349. PubMed ID: 33283248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
    JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical efficacy and safety of ixekizumab for psoriatic patients: a single-center experience.
    Burlando M; Salvi I; Castelli R; Herzum A; Cozzani E; Parodi A
    Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4060-4064. PubMed ID: 37203830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience.
    Calianno G; Esposito M; Fidanza R; Palmieri M; Fargnoli MC
    Dermatol Ther; 2021 Jul; 34(4):e14993. PubMed ID: 34029442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study.
    Li Y; Dang L; Lv C; Lin B; Tao J; Yu N; Deng Y; Wang H; Kang X; Qin H; Chen R; Li J; Liang Y; Liang Y; Shi Y
    Drug Saf; 2024 Jul; 47(7):711-719. PubMed ID: 38689136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García E; Herrera-Ceballos E
    Dermatol Ther; 2020 Nov; 33(6):e14202. PubMed ID: 32808703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.